[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20240949T1 - Hibridni interferoni za liječenje virusnih infekcija - Google Patents

Hibridni interferoni za liječenje virusnih infekcija Download PDF

Info

Publication number
HRP20240949T1
HRP20240949T1 HRP20240949TT HRP20240949T HRP20240949T1 HR P20240949 T1 HRP20240949 T1 HR P20240949T1 HR P20240949T T HRP20240949T T HR P20240949TT HR P20240949 T HRP20240949 T HR P20240949T HR P20240949 T1 HRP20240949 T1 HR P20240949T1
Authority
HR
Croatia
Prior art keywords
subtype
coronavirus
hybrid
interferon
prophylaxis
Prior art date
Application number
HRP20240949TT
Other languages
English (en)
Inventor
William Stimson
Original Assignee
Ilc Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003812.1A external-priority patent/GB202003812D0/en
Priority claimed from GBGB2012967.2A external-priority patent/GB202012967D0/en
Priority claimed from GBGB2102261.1A external-priority patent/GB202102261D0/en
Application filed by Ilc Therapeutics Ltd filed Critical Ilc Therapeutics Ltd
Publication of HRP20240949T1 publication Critical patent/HRP20240949T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (7)

1. Interferon alfa podtip, naznačen time što je interferon alfa podtip HIBRID 2 ili funkcionalno aktivni fragment SEQ ID NO: 3 za uporabu u liječenju i/ili profilaksi virusne infekcije; pri čemu je virusna infekcija infekcija koronavirusom i pri čemu HYBRID 2 sadrži ili se sastoji od aminokiselinske sekvence SEQ ID NO: 3 [image]
2. Interferon alfa podtip za uporabu u liječenju i/ili profilaksi virusne infekcije prema zahtjevu 1, naznačen time što je koronavirus teški akutni respiratorni sindrom koronavirus-1 (SARS-CoV-1), ljudski koronavirus NL63, ljudski koronavirus HKU1, bliskoistočni respiratorni sindrom koronavirus (MERS-CoV) ili teški akutni respiratorni sindrom koronavirus-2 (SARS-CoV-2 ili Covid19).
3. Interferon alfa podtip za uporabu u liječenju i/ili profilaksi virusne infekcije prema bilo kojem od zahtjeva 1 do 2, naznačen time što se interferon alfa podtip primjenjuje sublingvalnom, oralnom ili primjenom injekcije.
4. Interferon podtip prema zahtjevu 3, naznačen time što se interferon alfa podtip primjenjuje u niskoj dozi između 104 do 5x106 IU dnevno.
5. Pripravak koji sadrži interferon alfa podtip, pri čemu je interferon alfa podtip HYBRID 2 ili funkcionalno aktivni fragment SEQ ID NO:3, za uporabu u liječenju i/ili profilaksi infekcije koronavirusom pri čemu HYBRID 2 sadrži ili se sastoji od aminokiselinske sekvence SEQ ID NO: 3 [image]
6. Pripravak prema zahtjevu 5, naznačen time što nadalje sadrži antivirusni spoj.
7. Pripravak prema zahtjevu 6, naznačen time što je antivirusni spoj Remdesivir, LAM-002A, deksametazon ili Avigan.
HRP20240949TT 2020-03-16 2021-03-16 Hibridni interferoni za liječenje virusnih infekcija HRP20240949T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2003812.1A GB202003812D0 (en) 2020-03-16 2020-03-16 Compositions and methods relating to the treatment of diseases
US202063030074P 2020-05-26 2020-05-26
GBGB2012967.2A GB202012967D0 (en) 2020-08-19 2020-08-19 Compostions and methods relating to the treatment of diseases
US202063067930P 2020-08-20 2020-08-20
GBGB2102261.1A GB202102261D0 (en) 2021-02-17 2021-02-17 Compositions and methods relating to the treatment of diseases
EP21711947.8A EP4121092B1 (en) 2020-03-16 2021-03-16 Hybrid interferons for treating viral infections
PCT/GB2021/050649 WO2021186162A1 (en) 2020-03-16 2021-03-16 Hybrid interferons for treating viral infections

Publications (1)

Publication Number Publication Date
HRP20240949T1 true HRP20240949T1 (hr) 2024-10-25

Family

ID=77770690

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240949TT HRP20240949T1 (hr) 2020-03-16 2021-03-16 Hibridni interferoni za liječenje virusnih infekcija

Country Status (12)

Country Link
US (1) US20230203120A1 (hr)
EP (1) EP4121092B1 (hr)
JP (1) JP2023517525A (hr)
KR (1) KR20230020943A (hr)
CN (1) CN115697377A (hr)
AU (1) AU2021238925A1 (hr)
CA (1) CA3170629A1 (hr)
ES (1) ES2982915T3 (hr)
HR (1) HRP20240949T1 (hr)
HU (1) HUE067223T2 (hr)
PL (1) PL4121092T3 (hr)
WO (1) WO2021186162A1 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202102261D0 (en) * 2021-02-17 2021-03-31 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases
CN113440603B (zh) * 2020-03-26 2022-07-08 复旦大学 人α干扰素亚型及受体结合相关位点突变体在制备防治新型冠状病毒感染药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
GB201215873D0 (en) 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
ES2971046T3 (es) 2015-09-15 2024-06-03 Ilc Therapeutics Ltd Composiciones y métodos relacionados con el tratamiento de enfermedades

Also Published As

Publication number Publication date
US20230203120A1 (en) 2023-06-29
PL4121092T3 (pl) 2024-08-19
HUE067223T2 (hu) 2024-10-28
EP4121092C0 (en) 2024-04-24
ES2982915T3 (es) 2024-10-18
EP4121092A1 (en) 2023-01-25
EP4121092B1 (en) 2024-04-24
WO2021186162A1 (en) 2021-09-23
AU2021238925A1 (en) 2022-10-27
KR20230020943A (ko) 2023-02-13
JP2023517525A (ja) 2023-04-26
CA3170629A1 (en) 2021-09-23
CN115697377A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
HRP20240949T1 (hr) Hibridni interferoni za liječenje virusnih infekcija
MX2022010659A (es) Compuestos altamente activos contra la enfermedad por coronavirus de 2019 (covid-19).
AR036728A1 (es) Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico
HRP20171036T1 (hr) Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
HRP20211906T1 (hr) Dalargin za upotrebu u liječenju akutne respiratorne virusne infekcije
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
JP2005525784A5 (hr)
DK200300015A (da) Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer
MX2024001645A (es) Metodo para el tratamiento de las enfermedades virales veterinarias.
MX2022013195A (es) Uso de proteina surfactante d para tratar infecciones virales.
US4828830A (en) Method and composition for prophylaxis and treatment of viral infections
US7846430B2 (en) Composition and method for treating bovine papilloma virus in equine
WO2021225960A3 (en) Beta thymosin peptides for treating viral infections
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
JP2014510126A5 (ja) Ifnアルファ関連疾病の処置方法
MX2023007603A (es) Peptidos para el tratamiento de infecciones respiratorias de origen viral.
CA3242034A1 (en) Pharmaceutical composition for treatment of viral infections
NZ587372A (en) Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins
ES2052579T3 (es) Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.
WO2020139163A3 (ru) Комбинация противовирусных средств
SUN et al. Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
Mohammadabadi et al. Milk Lactoferrin: A Nutraceutical Supplement Against Viruses